MedTrace Logo

ORCA - Oracea® for Rosacea: A Community-based Assessment

NCT00892281 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1421

Last updated 2022-08-25

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.

Conditions

  • Rosacea

Interventions

DRUG

doxycycline (Oracea®) 40 mg modified release as monotherapy

Take once daily in the morning

DRUG

doxycycline (Oracea®) 40 mg modified release as add-on therapy

Take once daily in the morning

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Ronald W Gottschalk, MD · Galderma R&D

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892281 on ClinicalTrials.gov